Article

Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.

Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Japan.
Gynecologic Oncology (impact factor: 3.89). 01/2011; 121(2):390-4. DOI:10.1016/j.ygyno.2010.12.366 pp.390-4
Source: PubMed

ABSTRACT In recent years, cancer stem cells (CSCs) have been reported to be correlated with chemoresistance and may also be enriched in side populations (SPs). In this study, the relationship between resistance to paclitaxel (PTX) and cisplatin (CDDP) and side populations was examined in three parental PTX- and CDDP-sensitive ovarian cancer cell lines (2008, KF28, and TU-OM-1) and several other cell lines derived from these as well as the additional effects of interferon-alpha (INF-α).
SP of three different parental cell lines and PTX- and/or CDDP-resistant cell lines derived from these was analyzed with flow cytometry. The expression of ABCB1 and ABCG2 in KF28 and its derived cell lines was examined. Additional cell-death effect of INF-α with PTX was also examined.
In the three parental cell lines and the PTX-sensitive cell lines derived from these lines, SP was very low. Conversely, in PTX-resistant cell lines, regardless of CDDP resistance, SP increased. ABCB1 was strongly expressed in the PTX-resistant cells, but not in their parental lines, which are sensitive to PTX. While INF-α showed only slight enhancement of the cell-death effect of PTX in PTX-sensitive cells, INF-α itself strongly induced apoptosis in PTX-resistant cells regardless of PTX concentration.
The SP could be correlated with resistance to PTX. SP could be a target of INF-α, and resistance to PTX might be overcome by INF-α.

0 0
 · 
0 Bookmarks
 · 
33 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

Additional cell-death effect
 
additional effects
 
CDDP resistance
 
CDDP-resistant cell lines
 
CDDP-sensitive ovarian cancer cell lines
 
cell-death effect
 
cisplatin
 
derived cell lines
 
different parental cell lines
 
flow cytometry
 
parental PTX-
 
PTX-
 
PTX-resistant cell lines
 
PTX-resistant cells
 
PTX-sensitive cell lines
 
PTX-sensitive cells
 
recent years
 
side populations
 
slight enhancement
 
three parental cell lines